Revenues to September 30, 2017: +7%Continuing strong growth in theranostics sales: +27%Percentage of revenues from internal products maintained: 74%Croissy-Beaubourg and Montpellier, October 26, 2017, 6:00pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing…
Croissy-Beaubourg and Montpellier, October 16, 2017, 8:00am CET – THERADIAG (ISIN: FR0004197747, ticker: ALTER, eligible for PEA-PME equity savings plans in France), a company specializing in in vitro diagnostics and theranostics, today announces that its…
Excellent momentum for theranostics sales: +43%Second-quarter revenue growth: +12% Croissy-Beaubourg and Montpellier, July 25, 2017, 6 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, PEA-PME eligible), a company specializing in in vitro diagnostics and theranostics,…